| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.PHARMTHERA.2005.05.002 |
| P698 | PubMed publication ID | 15951022 |
| P2093 | author name string | Kenji Chiba | |
| P2860 | cites work | Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite | Q34339041 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoid tissue | Q3529455 |
| P304 | page(s) | 308-319 | |
| P577 | publication date | 2005-06-13 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors | |
| P478 | volume | 108 |
| Q57105996 | 7th EFIS Tatra Immunology Conference. Molecular determinants of T-cell immunity. 24-28 June 2006, High Tatra Mountains, Slovakia |
| Q43067167 | A Stability-Indicating HPLC Method for the Determination of Fingolimod in Pharmaceutical Dosage Forms. |
| Q89823404 | A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models |
| Q34349864 | A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin |
| Q35826151 | AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis |
| Q33611979 | Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. |
| Q36374498 | Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model |
| Q36804936 | Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal |
| Q50528880 | Apoptotic Diminution of Immature Single and Double Positive Thymocyte Subpopulations Contributes to Thymus Involution During Murine Polymicrobial Sepsis. |
| Q28270642 | Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis ? |
| Q33979875 | Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics |
| Q90351424 | Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways |
| Q43490293 | Clostridium butyricum CGMCC0313.1 Protects against Autoimmune Diabetes by Modulating Intestinal Immune Homeostasis and Inducing Pancreatic Regulatory T Cells |
| Q38402634 | Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. |
| Q41061525 | Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer |
| Q33912500 | Corneal blindness and current major treatment concern-graft scarcity. |
| Q37287769 | Current and future therapies for multiple sclerosis |
| Q38904928 | Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options. |
| Q36272747 | Development and Effects of FTY720 Ophthalmic Solution on Corneal Allograft Survival |
| Q39507555 | Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. |
| Q97587510 | Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii |
| Q38005193 | Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis |
| Q34612187 | Distinct roles for hematopoietic and extra-hematopoietic sphingosine kinase-1 in inflammatory bowel disease |
| Q36424053 | Drug discovery from natural products |
| Q44510150 | Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. |
| Q46836256 | Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues |
| Q36674475 | Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues |
| Q44826580 | FTY720 (fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats |
| Q37154788 | FTY720 (fingolimod) for relapsing multiple sclerosis. |
| Q37611085 | FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system |
| Q43235313 | FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. |
| Q36462344 | FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal |
| Q38458872 | FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice |
| Q24643383 | FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology |
| Q46246510 | FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow |
| Q35945171 | FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia |
| Q43262877 | FTY720, a sphingosine 1-phosphate receptor modulator, inhibits CD1d-restricted NKT cells by suppressing cytokine production but not migration |
| Q90456543 | Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors |
| Q35061388 | Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast |
| Q53294910 | Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis |
| Q46079105 | Fingolimod confers neuroprotection through activation of Rac1 after experimental germinal matrix hemorrhage in rat pups |
| Q42518240 | Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage |
| Q58608733 | Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes |
| Q37112554 | G protein-coupled receptors as therapeutic targets for multiple sclerosis |
| Q37209133 | G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors |
| Q44811888 | Gastric parietal cell atrophy and depletion after administration of a sphingosine-1-phosphate 1 inhibitor. |
| Q37917696 | How to find your way through the thymus: a practical guide for aspiring T cells. |
| Q41234936 | IL-4-secreting secondary T follicular helper (Tfh) cells arise from memory T cells, not persisting Tfh cells, through a B cell-dependent mechanism. |
| Q37785554 | Immunomodulatory drug treatment in multiple sclerosis |
| Q90638511 | In silico Docking Studies of Fingolimod and S1P1 Agonists |
| Q64063713 | Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage |
| Q82254328 | Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo |
| Q36384836 | Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). |
| Q37246683 | Interstitial leukocyte migration and immune function |
| Q38943724 | Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720. |
| Q39906123 | Knowns and unknowns in the future of multiple sclerosis treatment |
| Q90011129 | Leukocyte trafficking between stromal compartments: lessons from rheumatoid arthritis |
| Q26785848 | Lymphatic disorders after renal transplantation: new insights for an old complication |
| Q55281738 | More than Just an Immunosuppressant: The Emerging Role of FTY720 as a Novel Inducer of ROS and Apoptosis. |
| Q37001453 | Multiple sclerosis therapy: an update on recently finished trials |
| Q40336488 | Nanoparticulate fingolimod delivery system based on biodegradable poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV): design, optimization, characterization and in-vitro evaluation |
| Q89575447 | Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets |
| Q38283522 | Neuroinflammation after intracerebral hemorrhage |
| Q38205485 | Novel thiazole derivatives: a patent review (2008 - 2012. Part 2). |
| Q38164064 | Nutritional components regulate the gut immune system and its association with intestinal immune disease development |
| Q36830152 | Oral disease-modifying treatments for multiple sclerosis: the story so far. |
| Q37028758 | Orphan GPCR research |
| Q37325656 | Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable |
| Q42601315 | Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants |
| Q37685422 | Phenotype and Tissue Residency of Lymphocytes in the Murine Oral Mucosa. |
| Q55505620 | Potential immunotherapies for traumatic brain and spinal cord injury. |
| Q48029106 | Protective effect of FTY720 against sevoflurane-induced developmental neurotoxicity in rats |
| Q37419072 | Recent clinical trials and future therapies |
| Q93037335 | Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo |
| Q87242125 | Rethinking the roles of inflammation in the intracerebral hemorrhage |
| Q35140438 | Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge |
| Q35118828 | Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages |
| Q38650868 | Small molecules as therapy for uveitis: a selected perspective of new and developing agents. |
| Q37551932 | Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery |
| Q37148742 | Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis |
| Q33727889 | Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro |
| Q90680336 | Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis |
| Q55564395 | Sphingosine-1-Phosphate-Specific G Protein-Coupled Receptors as Novel Therapeutic Targets for Atherosclerosis. |
| Q92153267 | Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease |
| Q37675523 | Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis. |
| Q36299846 | Sphingosine-1-phosphate inhibits IL-1-induced expression of C-C motif ligand 5 via c-Fos-dependent suppression of IFN-β amplification loop |
| Q42511343 | Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis. |
| Q42962009 | Sphingosine-1-phosphate signaling in human submandibular cells |
| Q37501281 | Symbiont-derived sphingolipids modulate mucosal homeostasis and B cells in teleost fish |
| Q43274291 | Synergistic effects of Isatis tinctoria L. and tacrolimus in the prevention of acute heart rejection in mice |
| Q42094981 | Synthesis and spectral properties of cholesterol- and FTY720-containing boron dipyrromethene dyes |
| Q90341485 | Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis |
| Q24658001 | Targeting protein serine/threonine phosphatases for drug development |
| Q92446113 | Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma |
| Q40117186 | The CII-specific autoimmune T-cell response develops in the presence of FTY720 but is regulated by enhanced Treg cells that inhibit the development of autoimmune arthritis. |
| Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
| Q36072077 | The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. |
| Q38497590 | The primate autoimmune encephalomyelitis model; a bridge between mouse and man. |
| Q38159721 | The role of sphingosine-1 phosphate and ceramide-1 phosphate in trafficking of normal stem cells and cancer cells |
| Q84744062 | The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis |
| Q37229011 | Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier |
| Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
| Q42041166 | Thymic egress: S1P of 1000 |
| Q46428828 | Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection. |
| Q83265722 | Trial watch: Phase III promise for oral multiple sclerosis therapy |
| Q64076907 | Triggering the Resolution of Immune Mediated Inflammatory Diseases: Can Targeting Leukocyte Migration Be the Answer? |
| Q46210843 | Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator |
Search more.